Today, our belief in ProFibrix - and particularly in founder and CSO Jaap Koopman, PhD - has been justified with the news of their acquisition by The Medicines Company. This acquisition coincides with some very encouraging data from Phase III of the trial of Fibrocaps - an important biologic that helps limit bleeding in patients - and can help save lives.
From the very beginning, our backing of ProFibrix was an expression of our high degree of confidence in Jaap, in his very clear ideas and vision, and his lifelong experience in the fibrinogen space. True to form, in the six years since that initial round Jaap has kept the company’s focus on the original idea behind Fibrocaps.
The focus has remained ultra-sharp and in six intense years the company has progressed from a very early, pre-clinical stage initial idea into a completed Phase III company. That’s the reason to applaud Jaap as well as CEO Jan Öhrström, MD and Arnoud Dijkstra, PhD, Chief Business Officer, who held the same title when we worked with him at Pangenetics, when its PG110 anti-NGF antibody was acquired by Abbott Labs for $170 million.
We are also eagerly anticipating continued great successes with ProFibrix now part of The Medicines Company family. There simply could not be a better fit for ProFibrix than The Medicines Company, truly one of the most innovative players in pharma, and we commend Chairman and CEO Clive A. Meanwell, MD, PhD, for this move.